098 Disease severity and needs of patients with moderate-to-severe Atopic Dermatitis

The German Atopic Dermatitis (AD) registry TREATgermany includes patients with moderate-to-severe AD. To improve the understanding of AD, it is important to observe disease severity, treatment patterns, and patient needs in routine care. Standardized registry assessments include comprehensive questionnaires to capture general patient characteristics, disease severity, comorbidities, and systemic therapies by the physician as well as patient-reported outcomes such as quality of life, fatigue and depressive symptoms. In total, 1230 patients were enrolled in the registry until August 2021. The mean age of the included patients at baseline was 40.7 years (SD 14.7). 57.5% were men. According to objective SCORing Atopic Dermatitis (oSCORAD) index, 56.3% patients (n=690) were classified as having severe AD at baseline. This was accompanied by 51.6% (n=627) of the patients reporting to be very or extremely strongly impaired in their quality of life. 71.1% of the patients had received systemic immunosuppressive / immunomodulatory therapies in the past. Patients’ treatment-related needs that were most frequently rated as important were “to be free of itching” (97.2%) and “to regain control of the disease” (95.8%). Data from TREATgermany clearly indicate that moderate-to-severe AD constitutes a major burden to affected patients that is not limited to clinical disease signs and symptoms but includes all major aspects of patients’ everyday life. Patient-centered AD care should regularly include the assessment of patients’ treatment goals.